Share
News
1 - 2 of 2 news items
-
26 July 2010 /Product information
EMA reassesses cardiovascular safety of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim)
In July, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) once again initiated a review of the benefit-risk profile of rosiglitazone-containing medicines, which in Denmark are used to a very limited degree for the treatment of type 2 diabetes.
-
22 July 2010 /Product information
Updated monographs for Heparin calcium (0332) and Heparin sodium (0333) for implementation in the European Pharmacopoeia (Ph. Eur.) as of 1 August 2010
As a follow-up on the work on improving the analysis methods for potentially contaminated heparin preparations, the European Pharmacopoeia Commission has adopted two revised monographs for Heparin calcium (0332) and Heparin sodium (0333) which will be implemented in the European Pharmacopoeia (Ph. Eur.) from 1 August 2010.
